Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Int J Pharm. 2012 Jul 1;430(1-2):276-81. doi: 10.1016/j.ijpharm.2012.03.046. Epub 2012 Apr 1.
The nanoassemblies were prepared from N-octadecanoyl gemcitabine (NOG)/cholesteryl succinyl poly(ethylene glycol) 1500 (CHS-PEG(1500)) (5:1, mol/mol). They showed higher cytotoxicity than gemcitabine on HpG2 cell model. The amphiphilicity of NOG may improve permeation of prodrugs and destruction of cell membrane. The nanoassemblies were rapidly eliminated from circulation after bolus intravenous administration to healthy and tumor-bearing mice. The in vivo distribution sites of NOG were mainly liver and spleen though the distribution in tumor was not high. The non-spherical shape and high surface charge of the nanoassemblies may affect distribution. The nanoassemblies had similar anticancer efficacy to free gemcitabine solutions when the former contained about 1/3 dose of the latter in gemcitabine form. The nanoassemblies would be a promising anticancer nanomedicine.
纳米组装体由 N-十八烷酰基吉西他滨(NOG)/胆固醇琥珀酰聚乙二醇 1500(CHS-PEG(1500))(5:1,摩尔比)制备。它们在 HpG2 细胞模型上显示出比吉西他滨更高的细胞毒性。NOG 的两亲性可能会提高前药的渗透和细胞膜的破坏。纳米组装体在健康和荷瘤小鼠中静脉推注后迅速从循环中清除。NOG 的体内分布部位主要是肝脏和脾脏,尽管在肿瘤中的分布不高。纳米组装体的非球形形状和高表面电荷可能会影响分布。当纳米组装体中的吉西他滨含量约为游离吉西他滨溶液的 1/3 时,其抗癌功效与游离吉西他滨溶液相似。纳米组装体将是一种有前途的抗癌纳米药物。